Item 1.01. Entry into a Material Definitive Agreement.
On January 25, 2021 (the "Closing Date"), Aditx Therapeutics, Inc. (the
"Company") entered into a Securities Purchase Agreement (the "Purchase
Agreement") with an institutional accredited investor (the "Investor") for the
offering, sale, and issuance (the "Offering") by the Company of a $6,000,000
Senior Secured Convertible Promissory Note (the "Note"). Concurrently with the
sale of the Note, pursuant to the Purchase Agreement, the Company will also
issue a warrant (the "Warrant") to the Investor to purchase up to 800,000 shares
(the "Warrant Shares") of the Company's common stock, par value $0.001 per share
("Common Stock"). As a result of the Offering, the Company will receive
aggregate gross proceeds of $5,000,000.
The Note has a twenty-four month term and is convertible at the option of the
Investor at any time prior to maturity in shares of Common Stock (the
"Conversion Shares") at an initial conversion price of $4.00 per share, subject
to adjustment under certain circumstances. The Note will amortize in nineteen
(19) equal monthly installments (the "Installment Payments") starting the first
day of the sixth month after the Closing Date (each, an "Installment Date"). At
the Company's option, Installment Payments may be made in cash or in shares of
the Company's Common Stock. If the Company elects to repay in cash, the amount
payable shall be 105% of the applicable Installment Payment. If the Company
elects to repay in shares of Common Stock, the shares shall be priced at the
lowest of (i) the Conversion Price then in effect, and (ii) the greater of (x)
the Floor Price (as defined in the Note) and (y) the lower of 90% of the lowest
volume weighted average price (VWAP) of the Common Stock for each of the five
(5) Trading Days (as defined in the Note) ending and including the Trading Day
immediately prior to the applicable Installment Date.
All Installment Payments are subject to the Investor's right to (a) defer some
or all of any Installment Payment to a subsequent Installment Date or (b) to
convert an additional Installment Payment of the Note at the then-current
Installment Price until the next Installment Date. Upon the occurrence of an
Event of Default or a Change of Control (as such terms are defined in the Note),
the Note is subject to Redemption by the Investor. The Company is prohibited
from effecting a conversion of the Note to the extent that, as a result of such
exercise, the Investor, together with the its affiliates, would beneficially own
more than 4.99% of the number of shares of Common Stock of the Company
outstanding immediately after giving effect to the issuance of the such shares,
which beneficial ownership limitation may be increased by Investor up to, but
not exceeding, 9.99%.
The Warrant is immediately exercisable for a period of three (3) years at an
exercise price of $4.00 per share, subject to adjustment. After a period of one
hundred eight (180) days, if a registration statement covering the resale of the
shares of Common Stock underlying the Warrant is not effective, the holder may
exercise the Warrant by means of a cashless exercise. The Company is prohibited
from effecting an exercise of the Warrants to the extent that, as a result of
such exercise, the holder of the Warrant together with the holder's affiliates,
would beneficially own more than 4.99% of the number of shares of Common Stock
of the Company outstanding immediately after giving effect to the issuance of
the such shares, which beneficial ownership limitation may be increased by the
holder up to, but not exceeding, 9.99%.
Additionally, until the earlier of the (i) one year anniversary the Closing
Date, and (ii) such time as less than $2 million of aggregate Principal Amount
(as defined in the Note) of the Note remains outstanding, the Company is
prohibited from effecting or entering into an agreement to effect any issuance
of securities involving a Variable Rate Transaction (as defined in the Purchase
Agreement).
In connection with the Offering, the Company also entered into a registration
rights agreement (the "Registration Rights Agreement") with the Investor
pursuant to which the Company shall prepare and file with the U.S. Securities
and Exchange Commission (the "SEC") a registration statement (the "Registration
Statement") covering the Note, the Conversion Shares, the Warrant, and the
Warrant Shares and any additional shares of Common Stock issued and issuable in
connection with any stock split, dividend or other distribution,
recapitalization or similar event with respect to the foregoing (collectively,
the "Registrable Securities") on or prior to the 30th calendar day following the
Closing Date (the "Filing Date").
1
The Company shall use its best efforts to cause the registration statement
covering the Registrable Securities to be declared effective (the "Effectiveness
Date") no later than the earlier of the (i) 120th calendar day after the Closing
Date and (B) the 2nd Business Day after the date the Company is notified (orally
or in writing, whichever is earlier) by the SEC that such Registration Statement
will not be reviewed or will not be subject to further review. If, among other
things, the Company fails to file the registration statement by the Filing Date
or fails to have such Registration Statement declared effective by the
Effectiveness Date (the date on which such failure occurs, the "Event Date"),
then on each such Event Date and on each monthly anniversary of each such Event
Date until the applicable failure is cured, the Company shall pay to the
Investor, in cash, a fee equal to 2% of the Investor's original principal amount
included on the Note.
In connection with the Offering, the Company will issue Dawson James Securities,
. . .
Item 2.03. Creation of a Direct Financial Obligation or an Obligations under an
Off-Balance Sheet Arrangement of a Registrant.
Reference is made to the disclosure under Item 1.01 above which is hereby
incorporated in this Item 2.03 by reference.
Item 3.02 Unregistered Sales of Equity Securities.
Reference is made to the disclosure under Item 1.01 above which is hereby
incorporated in this Item 3.02 by reference.
Item 8.01 Other Events.
On January 26, 2021, the Company issued a press release announcing the
Offering. A copy of the press release is furnished as Exhibit 99.1 to this Form
8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
4.1 Form of Senior Secured Convertible Promissory Note
4.2 Form of Warrant
10.1 Form of Securities Purchase Agreement
10.2 Form of Registration Rights Agreement
10.3 Form of Placement Agent Warrant
99.1 Press release, dated January 26, 2021
2
© Edgar Online, source Glimpses